Corporate Sustainability Report

Overview

The report describes JB Pharma's FY 2024-25 sustainability progress, including about 37% of total energy demand met through renewable sources and zero reported cases of injuries, fatalities, and occupational diseases. It details the company's first double materiality assessment, considering both societal and environmental impacts and financial performance. The report also highlights a TCFD report, expanded ESG governance, and community healthcare initiatives reaching thousands of people.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024-2025
Period: 1 April 2024 – 31 March 2025
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview